Cytokinetics Profit Margin

The latest profit margin for CYTK is -1259.87% as of June 2026. That compares with -707.17% in the prior-year period — down 78.2% year over year. That is below the Healthcare sector average of 13.76%. Investors often review this figure alongside Cytokinetics's historical trend and sector peers before judging valuation or financial health.

Over the past year, CYTK's profit margin moved from -707.17% to -1259.87% — a 78.2% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Cytokinetics's valuation or profitability profile.

Against Healthcare companies, CYTK currently prints -1259.87% for profit margin, while the sector average sits near 13.76%. That is roughly 9255.8% below the sector mean. Large gaps often invite a closer look at Cytokinetics's growth, margins, and balance sheet.

Profit Margin shows how effectively Cytokinetics converts resources into returns. At -1259.87%, CYTK may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -707.17% in the prior-year period — down 78.2% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting CYTK's profit margin (-1259.87%), review year-over-year change from -707.17%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.